Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2025 financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets. The Company ...

In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on Argenx Se, with a price target of $750.00. The company’s shares closed last Friday at $591.99. Take advantage ...

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best biotech stocks to invest in now. On June 10, Travere Therapeutics launched a new awareness campaign called ‘Play It Forward’ to ...

Detailed price information for Ultragenyx Pharmaceu (RARE-Q) from The Globe and Mail including charting and trades.

The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new employee’s continued service relationship with Travere through the applicable ...

Institutional investors including Armistice Capital, RTW Investments, and Wellington Management have increased their exposure ...

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. (“Travere” or the “Company”) (NASDAQ: TVTX). Such ...

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. (“Travere” or the “Company”) (NASDAQ: TVTX). Such ...

Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 16, Leerink Partners analyst Joseph Schwartz reiterated the firm’s ...

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. (“Travere” or ...